2024
Implications of Atrial Fibrillation for Guideline-Directed Therapy in Patients With Heart Failure JACC State-of-the-Art Review
Newman J, O'Meara E, Böhm M, Savarese G, Kelly P, Vardeny O, Allen L, Lancellotti P, Gottlieb S, Samad Z, Morris A, Desai N, Rosano G, Teerlink J, Giraldo C, Lindenfeld J. Implications of Atrial Fibrillation for Guideline-Directed Therapy in Patients With Heart Failure JACC State-of-the-Art Review. Journal Of The American College Of Cardiology 2024, 83: 932-950. PMID: 38418008, DOI: 10.1016/j.jacc.2023.12.033.Peer-Reviewed Original ResearchConceptsGuideline-directed medical therapyAtrial fibrillationHeart failureAssociated with significant morbiditySpectrum of ejection fractionPrevention of AFIncidence of AFGuideline-directed therapyDiagnosis of AFEjection fractionSignificant morbidityMedical therapyJACC State-of-the-Art ReviewPatientsFrequent hospitalizationsIncreased life expectancyAssociated with greater symptom burdenCardiovascular conditionsGreater symptom burdenTherapySymptom burdenLife expectancyFibrillationHeartPrognosis
2023
Frequency and clinicoeconomic impact of delays to definitive diagnosis of obstructive hypertrophic cardiomyopathy in the United States
Naidu S, Sutton M, Gao W, Fine J, Xie J, Desai N, Owens A. Frequency and clinicoeconomic impact of delays to definitive diagnosis of obstructive hypertrophic cardiomyopathy in the United States. Journal Of Medical Economics 2023, 26: 682-690. PMID: 37170479, DOI: 10.1080/13696998.2023.2208966.Peer-Reviewed Original ResearchConceptsObstructive hypertrophic cardiomyopathyDefinitive diagnosisHypertrophic cardiomyopathyHCM diagnosisMedicare Supplemental databasesIBM MarketScan CommercialEmergency room visitsAdministrative claims dataMisclassification of patientsEligible patientsMarketScan CommercialMost patientsRoom visitsAlternative diagnosesPotential misdiagnosesCardiovascular conditionsInappropriate treatmentDatabase studyClaims dataHealthcare costsDiagnostic journeyPatientsEconomic burdenCurrent studyDiagnostic history